The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
An article from
Startup launches
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
Published June 18, 2026
Light micrograph of crypt architectural distortion in inflammatory bowel disease.
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
Biogen makes up to $1B deal for secretive anti-inflammatory biotech
Triveni Bio raises $65M ahead of upcoming readouts on eczema drugs
Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers
San Diego's cAMPfield Therapeutics raises $180M Series A backed by Novo Holdings, RA Capital and seven other top-tier life…
Kanvas Biosciences announced a $48 million Series A funding round, which will support a clinical trial later this year for the…
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates…
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech…
Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares…
